Pyruvate kinase (PK) activation specialist Agios Pharmaceuticals Inc (Nasdaq:AGIO) announced on Wednesday that the US Food and Drug Administration (FDA) has granted orphan drug designation to tebapivat (AG-946), a novel PK activator, for the treatment of myelodysplastic syndromes (MDS).
This designation supports the development of tebapivat as a potential new treatment option for patients with this rare disease.
Agios completed a Phase 2a study of tebapivat in lower-risk MDS late last year and is currently initiating a Phase 2b study.
Mitapivat, the company's lead PK activator, was previously granted FDA orphan drug designation for the treatment of PK deficiency, thalassemia and sickle cell disease.
Senhwa Biosciences' Silmitasertib gains rare paediatric disease designation for Neuroblastoma
Neuspera Medical names new chief operating officer
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
Dupixent shows promise in treating chronic spontaneous urticaria
Aisa Pharma receives orphan drug designation from FDA for AISA-021(cilnidipine)
Phanes Therapeutics doses first subject in clinical study of PT886 in combination with chemotherapy
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024
Diamyd Medical seeks Fast-Track approval for Type 1 Diabetes immunotherapy
Sun Pharma and Moebius Medical's MM-II receives Fast Track designation for osteoarthritis knee pain
Vivet Therapeutics receives Orphan Drug Designation from European Commission for VTX-806
SFA Therapeutics names new director of Biostatistics
FDA approves Azurity Pharmaceuticals' Nymalize oral solution in 30 mg/5 mL prefilled ENFit syringe